Investment
Features
FeesSafety
Academy
More
Pluang+

Blackrock files for a Bitcoin ETF that limits losses but caps gains using options and fixed income.

Market News
19 Oct 2026
Bitcoin
View Source
Neutral
Blackrock files for a Bitcoin ETF that limits losses but caps gains using options and fixed income.

Blackrock has filed with the SEC to launch the Ishares Bitcoin Managed Protection ETF (PBIT), designed to reduce investor losses by using options and fixed-income securities instead of directly holding bitcoin. The ETF aims to limit losses to about 10% per tranche through a strategy involving call options, but this does not guarantee a maximum loss for shareholders. While the fund offers downside protection, it caps potential gains, meaning investors may underperform bitcoin during rallies. The ETF is still subject to regulatory approval and will be managed by Blackrock Fund Advisors once effective.

Blackrock's filing for a Bitcoin ETF designed to limit investor losses offers context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 20, 2026 08:21 WIB: out of 50 major cryptocurrencies, 16 rose and 33 fell today. Notable movers include AVAX at Rp170.487 with a 3.12% decline and a typical hold time of 87 days, AAVE at Rp2.664.903 with a 2.92% decline and 100% buy order activity, and ATOM at Rp31.379 with a 2.88% gain and 76% buy order activity.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

The Jülich Supercomputing Centre and NVIDIA used the JUPITER supercomputer to simulate a universal 50-qubit quantum computer, surpassing their previous 48-qubit record from 2019. This full-state simulation required 2,048 TiB of memory, achieved throu...

Protocol Fundamentals
Bullish
4 hours ago
Sei (SEI) price forecast shows gradual rise to $2.02 by 2032 amid tech upgrades and market factors.

Sei (SEI) price forecast shows gradual rise to $2.02 by 2032 amid tech upgrades and market factors.

Sei (SEI) token price forecasts predict a gradual increase from around $0.08 in 2026 to an average of $1.72 in 2032, with a possible high of $2.02. These projections consider factors like adoption, ecosystem growth, market sentiment, and token vestin...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App